Kirkham B W, Davison S C, Corkill M M, Barbatis C, Panayi G S
Rheumatology Unit, United Medical School, Guy's Hospital, London, United Kingdom.
J Rheumatol. 1993 Jun;20(6):935-9.
To analyze the changes in soluble interleukin 2 receptor (sIL-2R) levels following treatment of patients with rheumatoid arthritis (RA).
Serial measurements of sIL-2R levels were made over 24 weeks in 40 patients with RA, treated with intramuscular (im) gold plus 3 im injections of either 120 mg methylprednisolone acetate or placebo.
sIL-2R levels were reduced in the glucocorticoid treated group in contrast to the gold only group, where levels initially increased. At 24 weeks, mean sIL-2R levels did not significantly differ from pretreatment levels in either group, despite improvements in clinical measures.
In our study, sIL-2R levels do not correlate with short term clinical measures of disease activity. Their significance for longer term prognostic use remains to be determined.
分析类风湿关节炎(RA)患者治疗后可溶性白细胞介素2受体(sIL-2R)水平的变化。
对40例RA患者进行了24周的sIL-2R水平连续测量,这些患者接受肌肉注射金制剂加3次肌肉注射120mg醋酸甲基泼尼松龙或安慰剂治疗。
与仅使用金制剂的组相比,糖皮质激素治疗组的sIL-2R水平降低,而仅使用金制剂的组中该水平最初升高。在24周时,尽管临床指标有所改善,但两组的平均sIL-2R水平与治疗前水平相比无显著差异。
在我们的研究中,sIL-2R水平与疾病活动的短期临床指标不相关。其在长期预后中的意义仍有待确定。